Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310312 | 0.84 | KDM4E (0.59) | HRH4IDO1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2762336 | 0.84 | KDM4E (0.59) | HRH4IDO1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31156446 | 0.82 | HRH4 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16339983 | 0.82 | HRH4 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8210176 | 0.82 | RHEB (0.43) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30295665 | 0.81 | FLT3 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL924331 | 0.81 | FLT3 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20505087 | 0.81 | FLT3 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15511675 | 0.81 | FLT3 (0.57) | HRH4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL915460 | 0.78 | HRH4 (0.55) | HRH4IDO1FLT3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| CN-102391251-A | Chemokine receptor antagonists | NOVARTIS AG | 2012-03-28 | — | — | CN | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| CN-1946713-A | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-5436337-A | Anticarcinogenic agents | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0297380-B1 | Indolyl propanols, process for their preparation, their uses and preparation containing them | BEIERSDORF LILLY GMBH (DE) | 1994-10-05 | — | — | EP | disclosed |
| EP-0579754-A1 | USE OF AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS | THE UPJOHN COMPANY (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992018089-A2 | USE OF STEROIDAL AND NON-STEROIDAL AMINES TO SENSITIZE MULTIDRUG-RESISTANT CELLS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
| US-4935414-A | New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds | BEIERSDORF AG (DE) | 1990-06-19 | — | — | US | disclosed |
| EP-0297380-A2 | Indolyl propanols, process for their preparation, their uses and preparation containing them | Beiersdorf-Lilly GmbH (DE) | 1989-01-04 | — | — | EP | disclosed |
| EP-0191724-A2 | 1,4-Dihydropyridine derivatives, their preparation and pharmaceutical compositions containing them | SANDOZ AG (CH) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | HRH4 478/4885IDO1 2338/4885GRIN2D 1646/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | HRH4 467/4885IDO1 2377/4885GRIN2D 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.